view more →
Clinipace is a clinical research organization whose services are enhanced by a proprietary on-demand software platform and clinical research services. Acquired by dMed in April 2021.
view more →
GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs.
view more →
The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor. IPO in October, 2018 (NASDAQ:PHAS)
